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Abstract
Colorectal cancer (CRC) is the third major cause of cancer-related deaths in the United States in
2020. Sex-related differences in CRC stage, prognosis, and metabolism have become
increasingly popular in cancer research. Males have poorer survival for CRC, but females with
right-sided colon cancer (RCC) have aberrant metabolism correlated with poor survival. Delay in
knowing the condition of CRC in female patients would result in poor prognosis, which could be
avoided by predicting prognostic outcomes. Random Survival Forest (RSF) is ideal for
exploration and making predictions using metabolomics data with high dimension, strong
collinearity, and heterogeneity, which CPH models could not efficiently address. In this
retrospective study including 197 patients, we applied an RSF prediction method based on the
backward selection algorithm in 5-year overall survival (OS) for 95 female CRC patients and
validated its performance. We also investigated Cox proportional hazard models (CPH), lasso
penalized Cox regression (Cox-Lasso), and Logistic Regression (LR) and compared their
predictive performances. RSF using the backward selection algorithm showed the best
performance with the C-index of the training and testing sets reaching 0.81(95% CI: 0.8100.813) and 0.78 (95% CI: 0.776-0.777) respectively and identified the five most predictive
metabolites for female 5-year OS: glutathione, citrulline, phosphoenolpyruvate, lysoPC (16:0),
and asparagine. Accordingly, the backward selection algorithm-based Random Survival Forest
model using tumor tissue metabolic profile is promising for predicting 5-year OS for female
CRC patients. The results could be easily interpreted and applied in preventive medicine and
precision medicine, guiding clinicians in choosing targeted treatments by sex for better survival
and avoiding unnecessary treatments.
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List of Tables
Table 1. Demographic Characteristics and Clinical Factors
Characteristics

No. of Patients

Age at diagnosis, y
55-60
19
61-69
64
70-79
81
≥80
33
Sex, n
Male
102
Female
95
Chemotherapy, n
Yes
66
No
131
Clinical stage, n
I
47
II
86
III
64
Anatomic tumor location, n
Left
99
Right
98

5-Year Overall Survival (OS)
Deaths, No. Rate, %a
P*
2
9
15
11

88.9
83.4
78.7
61.5

23
14

5-Year Recurrence-free Survival (RFS)
Cases, No. Rate, %a
P*

0.048

3
14
12
1

84.2
72.4
81.4
96.3

0.208

74.3
83.2

0.176

17
13

77.5
84.0

0.478

18
19

68.5
83.7

0.026

15
15

73.1
85.0

0.027

3
13
21

92.5
82.4
63.5

0.001

5
11
14

88.4
82.0
73.8

0.091

17
20

81.2
75.6

0.422

19
11

77.2
85.3

0.230

*

P value of Log-rank test.

a

Survival rates were calculated by the Kaplan-Meier estimation method.

Table 2. Results of fitting Cox model including sex, anatomic tumor location, clinical stage, and age on 5-year
OS and RFS of patients with colorectal cancer (n = 197)
Variables
Sex: male
Anatomic tumor location: RCC
Clinical stage: Late
Age

HR
2.05
0.84
4.17
1.09

OS
95% CI
1.04-4.05
0.42-1.68
2.11-8.24
1.05-1.14

1

P
0.039
0.623
<0.001
<0.001

HR
1.25
0.72
2.08
0.97

RFS
95% CI
(0.60, 2.59)
(0.33, 1.56)
(1.01, 4.27)
(0.92, 1.02)

P
0.555
0.410
0.047
0.261

Table 3. Primary exploration of predictive performance using RSF for CRC prognosis. The MPER might
slightly fluctuate due to randomness. MPER: Minimum prediction error rate.
Outcome

OS

RFS

Population

MPER

Selected metabolites

All patients (n = 197)

0.3085

CDP-Ethanolamine, CMP, Dimethylsphingosine, Glutathione,
disulfide, Hypoxanthine, Tyrosine

Females (n = 95)

0.2100

Asparagine, Citrulline, Creatinine, DHAPorG3P, Glutathione

Males (n = 102)

0.3407

Tyrosine, Uracil

All patients (n = 197)

0.3001

Acetyl-lysine, Cytidine, Dimethylsphingosine, Glutathione
disulfide, LysoPE (22:5), Palmitic acid, Xanthosine

Females (n = 95)

0.3257

Glutathione, Glutathione disulfide

Males (n = 102)

0.2356

Acetyl-lysine, Hypoxanthine, N1-Acetylspermine, Xanthosine

Table 4. Characteristics of training and testing sets for CRC female patients (n = 95).
Variables
Age (mean (SD))
Chemotherapy, n
Yes
No
Clinical stage
Early
Late
Anatomic tumor location
Left
Right
Death
Yes
No
Follow-up months (mean (SD))

Training set

Testing set

(n = 58)

(n = 37)

70.98 (8.03)

72.11 (7.51)

0.490

21
37

14
23

0.342

38
20

22
15

0.705

28
30

17
20

0.991

9
49
48.43 (19.30)

5
32
44.79 (21.87)

P*

1.000
0.560

P values calculated by Mann-Whitney U test for continuous variables; Chi square test or Fisher’s exact test for
categorical variables.
*
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Table 5. Results of COX1 and COX2 model with determined factors on 5-year OS of female CRC patients
based on the training set (n = 58). These two models were only for reference and comparison. They were invalid
for interpretation or making predictions because they violated the proportional hazard assumption. Additionally, a
small sample size with limited death events led to extremely high HRs. Thus, HRs were invalid and biased.

Model

COX1

COX2

Variables

HR (95% CI)

P

glutathione
glutathione disulfide
glycerol 3-phosphate
phosphoenolpyruvate
succinate
UDP-D-Glucose
Tumor location: RCC
Clinical stage: late
Age
glutathione
glycerol 3-phosphate
succinate
Tumor location: RCC
Clinical stage: late
Age

0.50 (0.20, 1.21)
1.08 (0.48, 2.44)
8.92 (1.17, 68.22)
1.26 (0.60, 2.65)
0.02 (0.00, 1.68)
1.23 (0.67, 2.25)
1.09 (0.14, 8.54)
66.29 (3.51, 1251.58)
1.27 (1.08, 1.49)
0.58 (0.39, 0.88)
9.43 (1.52, 58.55)
0.08 (0.01, 0.71)
1.60 (0.27, 9.55)
48.48 (4.87, 482.10)
1.25 (1.08, 1.44)

0.123
0.852
0.035
0.544
0.084
0.504
0.936
0.005
0.004
0.009
0.020
0.020
0.610
<0.001
0.003

Variable
violated PH
assumption
No
Yes
Yes
Yes
No
No
No
No
Yes
No
Yes
No
No
No
No

Model
violated PH
assumption

Model Cindex (Se)

Yes

0.949
(0.023)

Yes

0.952
(0.020)

Table 6. Variables with relative importance larger than 20% using RSF based on the training set (58 female
patients). VIMP: variable importance.
Variables

VIMP

Relative importance

Citrulline
Glutathione
Asparagine
LysoPC(16:0)
Clinical Stage
Creatinine
Glucosamine 6-phosphate
Age
Glycerol 3-phosphate
Taurine
Hypoxanthine

0.0228
0.0185
0.0117
0.0104
0.0096
0.0079
0.0078
0.0073
0.0057
0.0049
0.0047

100.00%
81.14%
51.45%
45.60%
41.88%
34.62%
33.97%
31.88%
24.84%
21.38%
20.69%
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Table 7. Comparing predictive performance for models in both training set and testing set. COX1 model
adopted statistically significant metabolites in individual analysis with clinical stage, tumor location, and age. COX2
model included remaining variables generated from COX1 after forward stepwise selection procedure with
minimum AIC. Cox-LASSO was a Cox regression model using all the variables with lasso penalty for feature
selection. RSF1 was constructed by the stepwise RSF backward algorithm with a minimum prediction error rate.
RSF2 used variables with VIMP > 0.005.
Models
COX1
COX2
Cox-LASSO
RSF1
RSF2
LR

C-index Estimates (95% CI)
Training set (n = 58)
Testing set (n = 37)
0.9494 (0.9043-0.9945)
0.6000 (0.3656-0.8344)
0.9448 (0.8938-0.9958)
0.6370 (0.4257-0.8483)
0.7056 (0.6903-0.7210)
0.6440 (0.6321-0.6558)
0.8117 (0.8104-0.8131)
0.7765 (0.7756-0.7773)
0.8469 (0.8462-0.8476)
0.6589 (0.6578-0.6600)
0.7732 (0.6090-0.9375)
0.6125 (0.3686-0.8564)
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List of Figures

Figure 1. Flowchart for the modeling process. RSF: random survival forest. LR: logistic regression. LASSO: least
absolute shrinkage and selection operator. K-fold CV: k-fold cross-validation. C-index: concordance index. External
validation: an important procedure to ensure sufficient robustness and generalizability using independent external
data sets after the models are tested to be valid from internal validation (the current data set we have).
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†

LysoPC: Lysophosphatidylcholine.

Figure 2. Sex differences in metabolites associated with CRC prognosis. Hazard ratios (HRs) for CRC by sex
for individual metabolites (per 1 standard deviation, adjusted for anatomic location, clinical stage, and age
(continuous)) (A) 5-year Overall survival (OS) and (B) 5-year Recurrence-free survival (RFS). A metabolite with
HR <1 was associated with a protective effect on prognosis; metabolite with HR > 1 was associated with an adverse
effect on prognosis. Metabolites with confidence intervals (CIs) marked with asterisks were significantly associated
with the presented prognosis (Raw P values < 0.05). All the metabolites abundance (continuous) was log 2
transformed. The x-axes are log-scaled. Sex interaction P values < 0.05.

6

Figure 3. Kaplan-Meier curve of training and testing sets. There was no statistically significant difference between
the survival of training and testing sets in log-rank test (P = 0.94).
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Remaining ariables with
coefficients 0:
Clinical stage, LysoPC(16:0)

Log( ) = -2.06

Log( )

Figure 4. Cox-LASSO modeling based on the training set (58 female patients). (A) 10-fold cross-validation
curve using the training set as a function of the λ with upper and lower standard deviation bar. The optimum λ
corresponded to the highest C-index. (B) a coefficient profile plot of the coefficient paths for a fitted Cox-LASSO
model using the training set. At Log(λ)= -2.06, only coefficients of two variables were not penalized to 0: Clinical
stage (coefficient = 0.3486) and lysoPC (16:0) (coefficient = 0.2178).

8

Figure 5. Partial 5-year predicted survival for nine most predictive variables on survival in colorectal cancer
data based on the training set (58 female patients). Values on the vertical axis represent predicted survival
probability for a given predictor after adjusting for all other predictors (A-I). (J) Error rates of RSF for log-rank
splitting rule. (K) Identified metabolites that are most predictive for 5-year OS among females by the minimal depth
measurement. Metabolites were identified using the random survival forest backward algorithm. Metabolites with
lower minimal depth values are more predictive regarding 5-year OS. Abbreviations LysoPC:
Lysophosphatidylcholine. Dark dots in A-F represented survivors, and blue dots represented dead patients.
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VIMP
Hypoxanthine
Taurine

Glycerol 3-phosphate
Age
Glucosamine 6-phosphate
Creatinine
Clinical Stage
LysoPC(16:0)
Asparagine
Glutathione
Citrulline
0

0.005

0.01

0.015

0.02

0.025

Figure 6. Variable importance (VIMP) for variables with relative importance larger than 20% based on the
training set (58 female patients)
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Figure 7. Prediction performance for Logistic Regression (LR). ROC curve for training set (n = 58) (A) and
testing set (n = 37) (B). ROC curve: receiver operating characteristic curve. AUC: Area under the ROC Curve. Pos
Pred Value: Positive prediction value. Neg Pred Value: Negative prediction value.

11

Figure 8. Prediction performance over time for the four models in the testing set (n = 37). RSF1 model had the
best predictive performance since month 20, followed by RSF2, COX2 and COX1. The dotted pink line indicates a
C-index = 0.75 as an acceptance threshold for a valid predictive model. The dotted grey line indicates a C-index =
0.5. Models with C-index < 0.5 were considered no better than predicting an outcome than random chance. RSF1
reached above the acceptance threshold after month 53.
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Introduction
According to CDC reports, colorectal cancer (CRC) is the third major cause of cancer-related
deaths in the United States in 20201. CRC survival is not only related to the stage at diagnosis
but is also strongly affected by the implementation of population-based screening that reduces
colorectal cancer incidence and mortality2. Studies have shown that conventional risk factors
included aging, family history of cancer, obesity, diets, alcohol consumption, smoking, low
physical activity, and socioeconomic status3. Clinical and pathological variables such as
inflammatory response, body mass index (BMI), tumor location and size, metastasis, lymph node
metastasis, and pathological stage of tumors also greatly influence CRC survival and have been
incorporated into prognosis prediction4. An emerging amount of new biomarker-based
approaches have been applied in colorectal cancer screening programs due to less invasiveness,
lower costs, and potentially higher detection accuracy, such as DNA methylation biomarker test
using blood samples5 and tumor endothelial marker test6. In addition, stratified screening
programs by risk factors including sex allow screening and preventive strategies to be targeted at
those most likely to benefit while reducing the number of patients undergoing harmful or
invasive tests, which unleash the potential to improve screening efficiency78.
Sex-related differences in CRC prevalence, prognosis, clinical stage, and metabolism have
become increasingly popular in cancer research91011. Males have poorer survival for CRC12.
However, females have a higher prevalence of right-sided colon cancer (RCC)12, which was
associated with and poor overall survival (OS)1314. Johnson Lab investigated untargeted
metabolomics on tumor tissue, looked at the biological mechanisms, and found a positive
association between aberrant metabolism in asparagine synthetase (ASNS) expression and poor
survival15, which laid the foundation of this study. These findings suggest that sex plays a vital
13

role in CRC prognosis together with the influence of anatomic tumor location, clinical stage, and
metabolism. Thus, it is promising to gain a complete view of how sex interacts with CRC
prognosis by addressing the clinical problem from the perspectives of metabolomics that helps to
reveal the biological background. Therefore, this study hypothesized that the untargeted
metabolic profile of primary tumor tissue metabolites could reveal sex differences in the
associations with CRC prognosis, and it could be used to predict CRC prognosis by sex.
A couple of studies have built robust prediction models for CRC prognosis in recent years using
clinical factors, biomarker data, and histopathological image data. Roshanaei et al. validated a
random survival forest (RSF) model to identify important risk factors (metastasis to other organs,
WBC count, disease stage, and the number of lymphomas) on mortality in CRC patients based
on their demographic and clinical-related variables16. Xu et al. used logistic regression (LR) to
predict the recurrence of stage IV CRC after tumor resection by considering time-to-event
outcome as a binary outcome (whether recurrence occurred)17. Bychkov et al. developed an
image-based deep learning approach to predict colorectal cancer outcomes based on images of
tumor tissue samples that outperform an experienced human observer in extracting more
prognostic information18. Kather et al. confirmed that convolutional neural networks (CNN)
were able to assess the human tumor microenvironment and predict prognosis directly using
histopathological images19. Biomarker-based prediction models such as the Circulating free
DNA (cfDNA) -based prognostic prediction model based on LASSO-Cox methods achieved an
excellent discriminating ability20.
There are multiple statistics and machine learning approaches available to build models for
prognosis prediction in clinical practice. In common, the Cox proportional hazards (CPH)
models are used to evaluate the relationships between cancer prognosis and risk factors.
14

However, CPH is sometimes not suitable for analyzing data with high dimension, complex
interactions between variables because it assumes that the outcome is a linear combination of
covariates21. The proportional hazard assumption is often violated in some survival data22 ,
which could produce biased hazard ratios. To avoid the defects of CPH, other non-parametric
models are more appropriate in this scenario. For metabolite data specifically, the exploratory
analysis of high dimensional metabolomic data containing hundreds of highly correlated
variables using regression approaches has unique statistical challenges related to multiple testing
and multicollinearity, which had been a major difficulty in this study. Multiple studies have
demonstrated that random survival forest (RSF) was a promising approach for identifying
disease-associated variables in complex time to event data with a large number of highly
correlated metabolites by utilizing a set of decision trees for prediction and ranking variables by
their importance232425. With RSF backward elimination procedure, Dietrich et al. successfully
extracted a series of informative metabolites for predicting type 2 diabetes mellitus (T2D) 5-year
disease-free survival, some of which showed nonlinear relationships with prognosis, indicating
the necessity of using RSF instead of CPH23. Likewise, our study also hypothesized that we
could find predictive metabolites for CRC prognosis using advanced statistical methods.
This study is a follow-up to the recent study at Johnson Lab, where we saw that high expression
of genes encoding metabolic enzymes were associated with poorer survival in females with
RCC15. We first looked at tumor tissue metabolites with sex differences in their associations with
CRC prognosis (5-year overall survival and 5-year recurrence-free survival) considering
anatomic tumor location, clinical stage, and age at diagnosis. Moreover, we examined the
possibility of making predictions for CRC prognosis using tumor tissue metabolome considering
sex difference, then identified predictive metabolites based on the RSF model for 5-year OS
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among female patients. Finally, we built several predictive models, compared their predictive
performances, and obtained the optimal one.

Methods and materials
Sample Collection and Metabolites Measurements
Metabolites were extracted and analyzed by hydrophilic interaction chromatography mass
spectrometry (HILIC-MS) and reverse phase liquid chromatography mass spectrometry (RPLCMS)-based metabolomics as previously described in an article by Cai et al.15. Only tumor tissue
samples from RCCs and LCCs within stage I-III (n=197) were selected in this study. Finally,
abundances of 91 metabolites were obtained.

Statistical Analysis
We included age, sex, anatomic tumor location, and clinical stage as covariates. Multivariable
Cox proportional hazard regression models were constructed to evaluate the associations
between prognosis with both individual metabolite abundance (1 SD differences on a log-scale)
adjusted for covariates for all patients and for both sexes. Two prognostic outcomes were
considered: 5-year overall survival (OS), 5-year recurrence-free survival (RFS). Due to the
absence of death events among females at clinical stage I, we recoded the clinical stages I and II
as “early stage”, and III as “late stage”. Patients with any types of chemotherapy prior to the
follow-up were coded as having chemotherapy history. Survival analyses were conducted using
package “survival” in R (version 4.0.4).

16

Random survival forest (RSF)
An RSF is computed by a cluster of binary decision trees that have been frequently used to select
the most important variables linked with time to event26. Minimal depth measurement is
implemented to assess how informative a variable is regarding the time until event23. Harrell’s
concordance index (C-index) is equal to 1- prediction error rate, which is commonly applied to
evaluate the predictability of a model. Random survival forest models were trained using the
“RandomForestSRC” R package. The RSF parameter number of trees and number of node splits
were fixed at 1000 and 10 initially. We applied a random survival forest backward selection
algorithm for variable selection to detect the most predictive and informative metabolites while
forcing covariates into our models23, which finally automatically chose the set of metabolites
producing the lowest prediction error rate. We used raw abundance in RSF modeling.

LASSO-based CPH
Regression with LASSO (least absolute shrinkage and selection operator) penalty is a commonly
used method for variable selection in a high‐dimensional data analysis that produces results
depend on the shrinkage parameter λ27. The R package “glmnet” was applied to Cox-LASSO
modeling based on 10-fold cross-validation.

Logistic Regression (LR)
Logistic regression (LR) can predict the probability of occurrence of an event by fitting data to a
sigmoidal S-shaped logistic curve28. Unlike survival models, LR dropped the time information
and coded the event within a certain length of time as a binary variable (e.g., survival during the
5-year of follow-up = 0, death within 5-year follow-up = 1).
17

Modeling process
We ran RSF based on the backward selection algorithm for all patients and by sex for 5-year OS
and RFS and then calculated minimum prediction error rates (MPER) for these six models that
were forced to include clinical stage, age, anatomic tumor location, chemotherapy as covariates.
MPER lower than 25% was considered as a standard indicating potential good predictive
ability16, and we only further investigate models with MPER < 25% in our study.
The whole modeling process could be summarized in Figure 1. To obtain a model with high
generalizability, it is essential to split the data set into a training set and a testing set. The training
procedure was conducted using an “inner” training set and validation set if we adopted the k-fold
cross-validation technique for parameter tuning based on the machine learning algorithm of our
choice. After multiple training cycles, we achieved a model with high fitting performance for the
“outer” training set with 60% of the samples. If the performance was poor, we considered it as
underfitting, and we would not proceed with further testing on the testing set. In this study, we
aimed to build models with C-index at least over 0.75 (equal to prediction error rate < 0.25) in
the training set (outer) that represented a promising potential of good predictive ability and then
to test them in the testing set. If the C-index for the fitted model on the testing set is high (>
0.75), the model is robust and generalizable and would be considered for external validation
using data from other independent cohorts. Otherwise, if the predictive accuracy is not high
enough, more valuable information should be collected and analyzed in future modeling for
improvement, and combination with other screening, testing approaches would be necessary as a
supplementation in clinical practice.

18

Results
Clinical characteristics
Baseline characteristics of 197 CRC cases (102 males and 95 females), including 5-year overall
survival (OS) and 5-year recurrence-free survival (RFS), are shown in Table 1. In the cohort, 37
total deaths and 30 recurrences were documented. The median follow-up time since the date of
surgery for primary tumor was 74.8 months (range, 0.1-169.2 months). Older age at which the
surgery was performed, having chemotherapy history, and advanced clinical stage were inversely
related to OS survival rate. For each subgroup by anatomic tumor location and clinical stage, the
demographic characteristics are displayed in Supplementary Table 1. Prognosis among different
subgroups is shown in Supplementary Table 2. Among these variables, chemotherapy history
was significantly associated with clinical stage for all patients (Wilcoxon rank-sum test P value <
0.001), and the treatment effects of chemotherapy on prognosis counteracted the harmful effects
of being late stages, which would make models hard to interpret. Thus, we believed that clinical
stage provided enough information, and we did not include chemotherapy history as a covariate
in the Cox Proportion Hazard (CPH). But we used both variables in other models using machine
learning algorithms that could carry feature selection automatically and produce interpretable
results.

Cox proportional hazard regression (CPH) analysis
In Table 2, sex was significantly associated with 5-year OS adjusted for anatomic tumor location,
clinical stage, age. We then examined the sex differences in the associations between OS and
metabolome and whether it was necessary to build different models by sex for prognosis
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prediction. Sex seemed to be independently associated with RFS but still conducted the same
analysis for RFS to see if any metabolites had sex heterogeneity in the associations with RFS.
We first analyzed the relationships between the abundance of 91 metabolites and OS.
Multivariate Cox proportional hazard (CPH) models estimated associations between 91 tumor
tissue metabolites and CRC prognosis individually by sex with 1 SD differences (log-metabolite
scale), adjusted for anatomic location, clinical stage, and age: 18 metabolites were significantly
associated with OS (Supplementary Table 3) for either female or male patients (Supplementary
Table 4). Twenty-five metabolites had statistically significant correlations with RFS for either
females or males (Supplementary Table 4). For both supplementary tables 3 and 4, the P values
were raw values before FDR adjustment. Only carnitine and hypoxanthine remained significantly
associated with RFS for males after FDR adjustment. Fig. 2 summarizes metabolites whose
associations with CRC prognosis differed by sex (interaction P values < 0.05).
Adenosine, asparagine, citrulline, glycerol 3-phosphate, LysoPC (16:0) (lysophosphatidylcholine
(16:0)), ornithine, succinate, threonine, UDP-D-Glucose, uracil, and xanthosine were found to
have significant sex differences in their associations with CRC OS (Supplementary Table 3, Fig.
2A). Among these 11 metabolites, succinate was associated with better OS for females
(HROS=0.34 per SD, 95% CI: 0.12-0.96, P = 0.042), while it was associated with poorer overall
survival for males (HROS=1.77 per SD, 95% CI: 1.21-2.58, P = 0.003) (Fig. 2A).
Argininosuccinic acid, asparagine, creatinine, hypoxanthine, and serine were found to have
significant but opposite associations with RFS between female and male patients (Supplementary
Table 4, Fig. 2B). These metabolites were all significantly associated with RFS in males but
were not associated with RFS in females. Interestingly, asparagine was observed to have sex
differences for both OS and RFS (Fig. 2). Asparagine was significantly associated with better
20

CRC prognosis in male patients (both OS and RFS): HROS=0.72 per SD, 95% CI: 0.55-0.96, P =
0.025; HRRFS=0.74 per SD, 95% CI: 0.56-0.98, P = 0.039, but there were no significant trends in
female patients (interaction POS = 0.029, interaction PRFS = 0.009) (Supplementary Table 3, 4).
None of the results in Fig. 2 violated the proportional hazards assumption.
Multivariate CPH analysis that includes all metabolites with clinical variables was inappropriate
because of strong collinearity and divergent results, given relatively small sample size and high
dimension with around 100 variables. Thus, we hoped to reduce dimension by Principal
Component Analysis (PCA). We tried to implement CPH analyses combined with PCA, but
there was no statistically significant result for OS among female CRC patients (Supplementary
Fig. 1, Supplementary Table 5, Supplementary Table 6). Thus, we sought other methods to
identify predictive metabolites.

Predictive modeling
Primary exploration of the possibility to predict CRC prognosis using tumor
tissue untargeted metabolic profile
The identified sex interactions indicated potential sex heterogeneity. Thus, we conducted
predictive modeling taking sex differences into account. We found that CPH models that
included all the metabolites to select features could not converge for all patients or both sexes,
even with stepwise selection methods. So, we turned to the Random Survival Forest algorithm
(RSF) to handle high dimensional data and collinearity problems without having to consider the
proportional hazard assumption. We ran RSF based on the backward selection algorithm for all
patients and by sex for 5-year OS and RFS and then calculated prediction error rates (PER) of
the model with selected variables together with clinical stage, age, anatomic tumor location,
chemotherapy as covariates. We further investigated models with minimum PER lower than
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25%, which was considered as a standard indicating potential good predictive ability in our
study. The selected metabolites were different by sex.
For example, the minimum prediction error rate for all patients was 0.3085 (Table 3). Thus, it
was not good to predict OS for all patients using our metabolomic profile based on RSF. It
seemed that predictive modeling using tumor tissue metabolome based on RSF for OS in females
and RFS for males was plausible with a minimum PER of 0.2100 and 0.2356, respectively
(Table 3). To justify the model, it is necessary to follow a standard machine learning modeling
process that split the data into a training set and testing set, and picked a trained model based on
the training set and tested it on the testing set (Fig. 1). It is worth mentioning that the training set
results might not be the same as results from the entire data set for 95 female CRC patients due
to sampling randomness. Furthermore, a successful random split would not cause too extreme
deviations between the two results. So far, this step was only meant to explore the possibility of
making predictions for different prognostic outcomes and populations. We could make
inferences using the results, but it would be better to test the findings in an independent data set.
Since we only obtained one cohort data, the only way is to split it into two independent parts to
for modeling, as Fig.1 described. We used a training set with 60% randomly selected patients to
select features and test it in a test set consisting of the remaining 40% patients.
For simplicity, in this thesis, we only further investigated models for OS for female patients with
a lower prediction error rate of 0.21 using the RSF algorithm. The entire dataset was split into
two independent groups, 60% for training and 40% for testing. There were no statistically
significant differences among the features of the two groups (Table 4). Mann-Whitney U test for
continuous variables; Chi-square test and Fisher’s exact test for categorical variables. The
difference in survival outcome was absent between the two sets as well (Fig. 3) so that the death
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events were balanced. Then it was safe to use the training set to generate a prediction model and
employ the testing set to estimate the model’s accuracy.

Cox proportional hazard regression (CPH) models with variable selection
using forward stepwise and LASSO
We built the first CPH model (COX1) with statistically significant metabolites in the individual
analysis with clinical covariates from the training set: glutathione, glutathione disulfide, glycerol
3-phosphate, phosphoenolpyruvate, succinate, UDP-D-Glucose (Table 5). Then we used forward
selection methods to select a group of variables with the least AIC (Akaike information criterion)
for CPH model (COX2) that included clinical stage, age, succinate, glycerol 3-phosphate, and
glutathione (Table 5). Recurrence status was correlated with OS (Fisher's Exact Test: P < 0.001),
but it should not be included in any of the models since this was observed simultaneously with
OS in practice. For COX1, the C-index was 0.9494 (0.9043-0.9945) for training set and 0.6000
(0.3656-0.8344) for testing set as shown in Table 7; for COX2, C-index was 0.9448 (0.89380.9958) for training set and 0.6370 (0.4257-0.8483) for the testing set. However, both models
violated the proportional hazard assumption, which might be due to nonlinear covariate
relationships or lack of independence that made the results less reliable. These two models in
Table 5 were only for illustration and reference; they were invalid for making predictions and
interpretation because the violations of the proportional hazard assumption produced biased
hazard ratios.
The variable selection methods for both COX1 and COX2 were primitively conducted manually,
and thus we turned to other methods suitable for addressing dimensionality reduction. CoxLASSO regression could use L1 penalty for feature selection and dimension reduction. Using 10fold cross-validation (C ), we tuned the λ parameter and selected the best one to produce a
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selected set of variables. We trained the Cox-LASSO in our training set, as shown in Fig. 4,
where the C-index peaked at 0.7173 when λ was around 0.1273 (Log λ = -2.06). When λ is very
small, the LASSO produced results similar to a CPH model with all the coefficients included. As
λ grew, the regularization term had a greater effect on penalizing more variable coefficients to
zero, leaving fewer variables in the model. Finally, only variables that were influential enough
were included in the model. The training process was summarized in Fig. 4. At Log(λ)= -2.06,
only two variables had coefficients > 0: Clinical stage (coefficient = 0.3486) and lysoPC (16:0)
(coefficient = 0.2178), both of which were positive indicating their contribution to lower overall
survival probabilities. We used this λ to test the prediction performance on the testing set, and we
got a C-index of 0.6667. To obtain a mean and 95% CI for the C-index for the training set and
testing set, we ran the model 1000 times, and the C-index was 0.7056 (0.6903-0.7210) for the
training set and 0.6440 (0.6321-0.6558) for the testing set as shown in Table 7.

Random survival forest (RSF) model
We first used the stepwise RSF backward algorithm by selecting a group of variables that
produced the best prediction performance using the training set. The model (RSF1) included
asparagine, citrulline, glutathione, lysoPC (16:0), phosphoenolpyruvate together with forcibly
included covariates (tumor stage, clinical location, age, and chemotherapy history), and the
prediction error rate reaches a minimum of 0.1883 (C-index=0.8117). Then we built an RSF
model (RSF2) including variables with relative variable importance (VIMP) > 5% (RSF1) for
both females: clinical stage, citrulline, chemotherapy history, age, hypoxanthine, glycerol 3phosphate, glutathione, asparagine, DHAPorG3P, and spermine (Table 6, Fig. 6). We ran the
models 1000 times to obtain their mean and 95% CI. RSF1 had a high C-index in the training set
of 0.8117 (95% CI: 0.8104-0.8131) and a lower C-index for the testing set 0.7765 (95% CI:
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0.7756-0.7773). RSF2 had a high C-index in the training set of 0.8469 (95% CI: 0.8462-0.8476),
but its C-index for the testing set is much lower (0.6589, 95% CI: 0.6578-0.6600).
The associations between the nine most predictive variables by RSF1 and OS are demonstrated
in Fig. 5. The estimated partial survival for a covariate indicates estimated survival for different
levels of the covariate after accounting for the average effects of the other selected metabolites
and the covariates. It can be seen from Figure 5, in continuous risk factor for example, as the
asparagine abundance increased up to about 4000, the 5-year predicted overall survival
probability decreases slowly from 95% to 90%, and then it decreased at a sharper rate until reach
65% (Fig. 5A), and a similar trend was found in citrulline (Fig. 5B). Glutathione, lysoPC (16:0)
and phosphoenolpyruvate had nonlinear relationships between predicted survival probability
their abundances with several turning points in their plots. For categorical variables such as
anatomic tumor location, right-sided cancer (RCC) demonstrated a lower 5-year predicted
survival estimated at around 5% compared with LCC on average (Fig. 5I), which agreed with
many previous findings2930. Female patients with chemotherapy history or at the late clinical
stage had about a 5% lower probability of survival. As Fig. 5J shows, the prediction error rates
decreased drastically and became stable and stayed around 0.18 as the number of trees grew to
1000. It is worth mentioning that calculation methods for these partial survival plots were not the
same as Kaplan–Meier curve or CPH models, and RSF models do not have to observe the
proportional hazard assumption.

Logistic regression model (LR)
Logistic regression (LR) was not the same as other methods that treated the data as time-to-event
data. Instead, it neglected the survival time and coded the death event as a binary variable
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(survival = 0, death = 1). The methods simplified the question into predicting “whether the
patient would die or not within the 5-year interval” without considering when the death would
occur. The predictive performance in the training set was better than the testing set, which
indicated a typical overfitting problem within the LR method (Fig. 7): LR had good specificity
(0.875) but inferior sensitivity (0.200). High specificity demonstrated this method had a strong
ability to correctly designate an individual who would not die in 5 years as a survivor, which
would help avoid unnecessary financial costs or mental burden for CRC patients. Low sensitivity
corresponded to more false-negative results, and thus more events of death within 5-years would
be not be anticipated, resulting in losing opportunities for early preventive intervention for CRC
female patients. The low sensitivity made its AUC (area under the curve) for the testing set
relatively low with a lower bound below 0.5. As a result, this method should be improved before
being used in clinical practice.

Comparing predictive performance for the models
The performances of these five models were evaluated based on C-index (1-prediction error
rate). A C-index larger than 0.75 is desired and indicates a good model. C-index < 0.5 indicates a
poor performance meaning that the model is no better than predicting an outcome than random
chance. 95% CI that includes 0.5 is considered to be not significant. For RSF1, RSF2, and CoxLASSO, 95% CIs were calculated by running the models in the testing set 1000 times. COX1
and COX2 fit the training data well with less error rate than other methods. However, their
predictive abilities in the testing set were not satisfying, with a lower bound of 95% CI below 0.5
(Table 7). Again, COX1 and COX2 were invalid and were just for comparison because of biased
hazard ratios due to violations of the proportional hazard assumption. RSF1 model outperformed
in predicting female 5-year OS with two stable and relatively high C-indexes of 0.8117 (95% CI:
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0.8104-0.8131) and 0.7765 (95% CI: 0.7756-0.7773) for the training set and the testing set,
respectively; both were above the acceptance threshold of 0.75. Results show an overfitting
problem with RSF2 as its performance in the training set (C-index = 0.8469, 95% CI: 0.84620.8476) was good, while its prediction error in the testing set was huge (nearly 0.34). CoxLASSO had problems of underfitting with the lowest C-index for the training set among the six
models (C-index = 0.7056, 95% CI: 0.6903-0.7210), though the performance was more stable
than LR. For future clinical practice purposes, RSF1 has the potential to be accepted if updated
using other established clinical and biological variables combined with other screening
measurements. Other models suffered from either underfitting or overfitting with a lack of
robustness in the testing set.
The prediction performances over time of COX1, COX2, RSF1 and RSF2 were examined as
shown in Fig. 8. The predictive abilities of the four models in the testing set were examined over
time (the testing set did not have a death event before month 20). All four models showed better
predictive abilities at a later time. RSF1 had a stably good prediction performance since month
30 in general. C-index of RSF1 during month 30 to month 40 hit 0.75, then dropped a little bit
before month 53, and soon reached above 0.75, indicating a promising possibility of predicting
OS at any time during 3-5 years.
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Discussion
This study is the first cohort using untargeted metabolomics to investigate possible associations
between 91 tumor tissue metabolites and colorectal cancer prognosis. Our analyses on individual
metabolites identified 11 metabolites with sex interactions in the associations with colorectal
cancer 5-year overall survival (OS) and five metabolites for 5-year recurrence-free survival
(RFS), among which asparagine was observed to have sex dimorphisms for both OS and RFS.
These findings suggest that different metabolism by sex were associated with different CRC
prognostic outcomes, and it was vital to build targeted predictive models by sex from the point of
view of precision medicine. By applying an RSF backward selection procedure within the
training set for female CRC patients (n = 58), five metabolites were identified to be most
predictive for the 5-year OS: glutathione, citrulline, phosphoenolpyruvate, lysoPC (16:0), and
asparagine. As demonstrated by the RSF1 model that incorporated these five metabolites might
provide new insights to the prediction of colorectal cancer 5-year OS for female patients when
used together with known epidemiological risk factors of CRC (clinical stage, chemotherapy
history, anatomic tumor location, and age). The comparison of the C-index (1- prediction error
rate) of five other different models revealed that especially noise metabolites were removed by
the RSF backward selection process, resulting in identifying the most predictive metabolites. In
contrast, RSF2 that included relative variable importance > 20% showed a better fitting
performance in the training set than RSF1, but it could not achieve a comparable C-index in the
testing set, which suggested its poor generalizability due to overfitting. Moreover, the
visualization by partial plots revealed nonlinear associations between the abundance of identified
metabolites and predicted 5-year overall survival, indicating possible diagnostic cut points for
further research.
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Our exploratory analyses and modeling indicated that traditional hazards-based models such as
CPH were not designed for prediction but to infer variables’ impact on a prognostic outcome21,
and were too primitive for high-dimensional metabolomics data. Instead, machine learning
algorithms performed better in predicting prognosis when we faced nonlinear interactions that
were presented in Fig. 5, which would violate the linear proportional hazards condition (Table
5). For example, Fig.5 I showed that RSF successfully distinguished the difference in 5-year
predicted survival between right-sided cancer (RCC) and left-sided cancer (LCC), which might
be hidden under the complex interactions between anatomic tumor location and tumor tissue
metabolites. As expected, none of the CPH models discovered the location-specific difference, as
CPH could not handle intricate inner interactions between metabolites and clinical variables so
explicitly. A similar modeling process to model nonlinear gene interactions made comparisons
between CPH and other machine learning methods, including RSF, which also proved the
applicability of automatically assessing nonlinear effects and complex interactions by RSF21.
These data-driven machine learning algorithms are unaffected to problems due to their natures
that perform robust feature selection against multicollinearity internally. As a result, collinearity
between variables did not impair the predictive accuracy and satisfied our goal of disengaging
from multicollinearity problems21. In our study, RSF has also shown its ability to outperform
classic CPH regressions at any time within the 5-year follow-up. As can be seen in Table 7, the
two CPH models COX1 and COX2, had very high C-index in the training set, while they failed
to handle the testing set. RSF1 using the backward selection algorithm showed the best
performance, with the C-index of the training and testing sets reaching 0.812 and 0.777,
respectively. The performance of RSF1 kept at a steady high C-index over time since month 20.
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Interestingly, the variables with coefficients larger than 0 in the Cox-LASSO model were lysoPC
(16:0) and clinical stage, which were also selected as predictors in RSF1 and RSF2, while COX1
and COX2 did not include the lysoPC (16:0) metabolite. LysoPC (16:0) had a significant sex
difference in overall survival in the individual metabolite analysis and was a risk factor for
female OS (HROS=1.54 per SD, 95% CI: 1.04 - 2.27, P = 0.031). Cai et al. found that the
lysophospholipids lysophosphatidylcholine were upregulated in women with RCC (stage I) but
not in men, suggesting that the higher levels of lysophospholipids in women with RCC would
promote fatty acid supply15 that was essential for cancer cell growth31. These findings justified
our findings identifying lysoPC (16:0) as an important predictor for CRC prognosis for females.
We also found that asparagine was an essential metabolite for female prognosis. Asparagine had
sex interactions with both OS and RFS and was tested to be an important predictor in both RSF1
and RSF2 models. Asparagine (Asn) abundance was associated with lower probabilities of
overall survival, which agreed with the previous finding of female survival and asparagine
synthetase (ASNS) expression15. Johnson Lab found that asparagine increased threonine uptake in
females RCCS that were nutrient deplete and could lead to aggressive phenotypes in those
patients15. In Fig.2, asparagine and threonine were all not significantly associated with OS for
female patients but were both associated with better OS for males. In cancer research based on in
vitro experiments, ASNS catalyzed asparagine was crucial for cancer cell growth by promoting
cancer cell amino acid homeostasis, anabolic metabolism, proliferation32, and Asn availability in
vitro strongly interplayed the metastatic progression of breast cancer33. For CRC specifically,
SOX12 expression promoted colorectal cancer cell proliferation and metastasis and facilitated
ASNS expression34. Another frequently found mutation in the KRAS gene in colorectal cancer35
was observed with a marked decrease in aspartate level and increased asparagine level by an
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upregulated ASNS expression, which indicated that ASNS might be a novel therapeutic target for
KRAS-mutant CRC 36. Moreover, SLC25A22 served as an essential metabolic regulator for CRC
progression by promoting the synthesis of aspartate-derived amino acids (asparagine) in KRASmutant CRC cells37. Knott et al. reported that increased dietary asparagine in animals promotes
metastatic progression in breast cancer, and dietary asparagine restriction inhibits metastasis
without affecting the primary tumor growth38. The study drew great attention from academics
and the media worldwide in 2018, ranked the 97th percentile (ranked 24th) of the 896 tracked
articles of a similar age in Nature on Altmetric39. According to BBC News, researchers from
Cambridge University claimed that patients with specific cancers might have developed an
addiction to specific components of diets, and it may be necessary to modify a patient’s diet or
change the way tumor cells get access to those nutrients with potential risks using drugs40.
Consequently, both internally produced asparagine and external exposure to asparagine may
influence CRC tumor progression. These studies provided strong evidence to support our
identification of asparagine as a predictive risk factor of OS for female CRC patients.
Besides, application of RSF with backward selection for all 95 female patients revealed that
creatinine was a predictive factor for 5-year OS. Creatinine was found to be a valid variable for
predicting CRC cases41 and was also reported with correlations to colon cancer based on other
studies of urine42 and serum43 samples from colon cancer patients. Also, creatinine is a measure
of cachexia, a syndrome characterized by unintentional weight loss44. The female patients we
studied were all over 55 years old (with an average age of 71), which might allow us to identify
creatinine as a predictive metabolite. However, whether creatinine has predictive ability among
other age groups requires further investigations.
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Some of the metabolites we observed might have multiple uses and are not just used by the
cancer cells, such as polyamine, which could be used by both colon cancer cells and bacterial
cells to build biofilms in colon adenomas/carcinomas45. Among the identified metabolites,
asparagine utilization could be regulated by L-glutamine via gut microbiota46. Hence if the
environmental milieu of the colon or rectum differs between males and females, it could
determine how metabolites are used and thus affect cancer progression.
Admittedly, because of the heterogeneity of different metabolomics data, there is no panacea
model for predicting CRC based on any types of metabolomics data. The flowchart in Fig. 1
illustrates a flexible, dynamic path for disease-related metabolomics research discovery. An
increasing number of biomedical studies utilizing Automated Machine Learning (AutoML)
methods have been applied to diseases such as cancer47, Alzheimer’s disease48, and
cardiovascular diseases49, which leveraged advances in hyperparameter search and model
selection based on metabolomics. Those studies used greater numbers of machine learning
algorithms and selected the optimal ones that suit their data best. Therefore, chances are that the
best model we built might not be the optimal one for our data, though random forest-based
models tend to be more stable than the simple decision tree model. Nevertheless, this study could
offer some insights into using metabolome to predicting CRC prognosis accounting for sex
differences for future studies.
The strength of this study is the application of untargeted metabolomics for CRC tumor tissue in
a well-described population-based retrospective cohort with strictly standardized study protocols
and a decades-long follow-up time. Tumor tissue metabolites have advantages over biomarkers
extracted from blood and urine samples because tumor tissues directly reflect tumor
microenvironment and metabolism, whereas components of other biofluids are liable to external
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environmental interactions such as dietary intake. Also, tumor tissue samples are easier to store
and more reliable for evaluating and predicting long-term prognosis than plasma samples that
tend to degrade in hours or days50. In addition, Cai et al. discovered that CRC tumor tissue
metabolites also differed by anatomic tumor location, and females with RCC were at higher risks
of poor overall survival15, implying that studying sex differences in prognosis should include
tumor location. Hence tumor tissue metabolic profiling considering tumor location was the
optimum approach.
Nonetheless, we should also admit the huge gap between real-world medical practice and
bioinformatics studies due to low reproducibility, even some of which claimed to provide robust
models. Evaluation of 184 studies on new prognostic markers of outcomes in acute pancreatitis
showed that only 15% had a sample size > 100 patients, and < 40% reported information about
patient recruitment, and none had power calculations51. Lack of replication efforts, small sample
sizes, insufficient subsequent external validation, unclear evaluation criteria were the major
causes of the failures in cancer biomarker discovery and translation along the biomarker
pipeline525354. There is still a long way to go before our findings are applied to actual medical
practice for colorectal cancer, such as providing risk scores by measuring tumor tissue metabolic
profile. Despite these possible defects and obstacles, this study could provide hints about
predictive prognostic biomarkers for colorectal cancer from the perspectives of sex difference
and tumor tissue metabolome.
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Conclusion
We identified five predictive metabolites for female CRC patients that could be used to predict
5-year overall survival using the random survival forest (RSF) backward selection algorithm. We
concluded that the RSF prediction method based on the backward selection algorithm was
promising in predicting 5-year overall survival (OS) for female CRC patients. The results could
also justify the urgent need for personalized CRC screening programs by sex or other factors
which benefit a targeted group of the population at higher risks with optimal resource allocation.
Due to a large number of correlated variables that brought problems of multiple comparison,
insufficient statistical power, and higher risks of multicollinearity, false-positive detection with
significant P values by chance are sometimes unavoidable in exploratory data analysis of
complex metabolomic data based on traditional statistical regression approaches. Moreover, most
metabolites identified with sex differences in CRC prognosis had insignificant P values after
FDR adjustment., which need future replication studies to confirm their associations with CRC
prognosis and sex differences. Fortunately, we were able to take advantage of bootstrapping and
the interruption of intercorrelation structures by random node splitting to reduce overfitting,
multicollinearity, and select reliable predictive variables using RSF. Furthermore, nonlinear
relationships between the identified metabolites and predicted survival time could be visualized
to determine potential clinical thresholds after validated in further population studies.
The predictive performance of this method in the training set was satisfactory (C-index = 0.81),
and the prediction accuracy in the testing set was slightly lower but still acceptable (C-index =
0.78). The model is reliable in the statistic aspect but may need further improvement in clinical
practice that requires much higher accuracy. Several limitations might lead to these results: 1) a
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small sample size with limited death event for data mining could only provide limited
information; 2) established covariates for predicting CRC development and poor prognosis were
absent in our data set, such as genotype, family history, metastasis, BMI, dietary factors, alcohol
consumption, smoking behaviors; 3) incomplete information of the treatment or drug history
within the follow-up period. The already good predictive accuracy in the testing set laid the
foundation for improving the prediction performance after adding more variables mentioned
above using a larger cohort. Moreover, it is also helpful to conduct a multi-omics analysis that is
more comprehensive than metabolomics alone. Afterward, several external validation processes
using independent cohort data are necessary before being applied to clinical practice. We foresee
the enormous potential of using novel biomarkers to predict prognosis by multi-omics
approaches based on machine learning, statistical learning methods.
Ultimately, my recommendations for the YSPH MPH program would be to set up new courses
focusing on biomarker discovery for cancer epidemiology (both methodology, data analysis, and
causal inference).
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Appendix
Supplementary Table 1. Demographic characteristics and clinical factors for each subgroup. RCC = right-sided colon cancer, LCC = left-sided colon cancer.
Stage I (n=47)
Stage II (n=86)
Stage III (n=64)
Subgroup
RCC
LCC
RCC
LCC
RCC
LCC
(n=22)
(n=25)
(n=44)
(n=42)
(n=32)
(n=32)
Sex, n
Males
10
15
23
25
15
14
Females
12
10
21
17
17
18
Age, mean (SD)
Males
73.9 (6.5)
69.3 (5.8)
72.9 (7.8)
72.2 (8.5)
73.5 (7.8)
63.7 (5.8)
Females
72.1 (6.2)
69.6 (7.6)
73.5 (9.8)
69.1 (7.8)
72.2 (6.6)
71.1 (6.0)
5-year Overall survival rate, %a
Males
87.5
85.1
76.5
74.1
47.1
78.6
Females
100
100
82.9
100
65.2
61.8
5-year Recurrence-free survival rate, %a
Males
90.0
78.3
86.8
67.6
82.1
70.1
Females
90.9
100.0
87.5
87.4
76.0
68.8
a
The survival rates were calculated using the Kaplan-Meier estimation method.
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Supplementary Table 2. Prognosis among different subgroups of patients after combining stage I and II together to allow analysis of Anatomic location: RCC
vs. LCC females
5-year Overall Survival (OS)
Subgroup
RCC males
RCC females
LCC males
LCC females
c
Event
0
1
0
1
0
1
0
1
Stage aa
28
5
30
3
32
8
27
0
b
Stage b
8
7
12
5
11
3
12
6
Total
36
12
42
8
43
11
39
6
5-year Recurrence-free Survival (RFS)
Subgroup
RCC males
RCC females
LCC males
LCC females
d
Event
0
1
0
1
0
1
0
1
Stage aa
30
3
30
3
32
8
25
2
b
Stage b
13
2
14
3
10
4
13
5
Total
43
5
44
6
42
12
38
7
a

Stage a combines Stage I and II together which refers to earlier stages.
Stage b refers to Stage III.
c
Event = death. 1= the event occurred within 5 years of follow-up, 0 = the event did not occur within 5 years of follow-up (survived or censored).
d
Event = recurrence. 1= recurrence occurred within 5 years of follow-up, 0 = recurrence does not occur within 5 years of follow-up. If a patient died before CRC
recurrence, it will be counted towards a death event.
b

Notes:
If a patient died for any reason without recurrence within follow-up time (no more than 5 years), it was only counted toward a death event in OS.
If a patient experienced recurrence but did not die within follow-up time (no more than 5 years), it was only counted toward a recurrence event in RFS.
If a patient experienced recurrence and then died within follow-up time (no more than 5 years), it was counted toward a recurrence event in RFS and a death
event in OS.
If a patient experienced neither recurrence nor death within follow-up time (no more than 5 years), the event was 0 for both OS and RFS.
Due to the absence of death events among females at clinical stage I, we regarded stage I and II patients as “stage a” (early stage) and stage III patients as “stage
b” (late stage). Still, all the LCC females

2

Supplementary Table 3. Associations between individual metabolites and 5-year overall survival (OS) by sex, adjusted for anatomic location, clinical stages,
and age).
Females
Males
Metabolite name
Int. Sex P value *
HR
95% CI
P valuea
HR
95% CI
P valuea
0.342
Acetyl-lysine
0.96
0.74 - 1.25
0.786
0.83
0.72 - 0.96
0.012
0.044
Adenosine
0.91
0.70 - 1.19
0.507
1.29
1.03 - 1.62
0.026
0.096
Alanine
1.05
0.77 - 1.42
0.762
0.77
0.61 - 0.98
0.034
0.154
Argininosuccinic acid
0.93
0.71 - 1.23
0.613
0.74
0.58 - 0.93
0.010
0.029
Asparagine
1.45
0.87 - 2.42
0.154
0.72
0.55 - 0.96
0.025
0.881
Carnitine
0.62
0.04 - 9.47
0.733
0.56
0.34 - 0.93
0.026
0.002
Citrulline
1.66
0.98 - 2.81
0.061
0.65
0.46 - 0.92
0.014
0.017
Glycerol 3-phosphate
3.64
1.30 - 10.2
0.014
0.91
0.47 - 1.77
0.777
0.444
Hypoxanthine
1.04
0.35 - 3.13
0.943
0.65
0.44 - 0.95
0.027
0.008
LysoPC(16:0)
1.54
1.04 - 2.27
0.031
0.85
0.66 - 1.11
0.244
0.316
Ornithine
0.96
0.56 - 1.66
0.895
0.68
0.47 - 0.97
0.035
0.035
Serine
1.24
0.65 - 2.38
0.519
0.55
0.37 - 0.81
0.002
0.086
Spermine
1.40
1.01 - 1.93
0.041
1.03
0.83 - 1.27
0.813
0.004
Succinate
0.34
0.12 - 0.96
0.042
1.77
1.21 - 2.58
0.003
0.035
Threonine
1.11
0.67 - 1.86
0.685
0.61
0.44 - 0.85
0.004
0.012
UDP-D-Glucose
0.81
0.67 - 0.97
0.023
1.15
0.95 - 1.40
0.161
0.024
Uracil
1.21
0.54 - 2.69
0.643
0.44
0.28 - 0.70
0.001
0.027
Xanthosine
1.21
0.86 - 1.71
0.283
0.71
0.54 - 0.94
0.016
a

Raw P value before FDR adjustment. *Each metabolite with sex-interaction P value. The abundance of each metabolite was treated as a continuous variable and
was log2 transformed.
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Supplementary Table 4. Associations between individual metabolites and 5-year recurrence-free survival (RFS) by sex, adjusted for anatomic location, clinical
stages, and age).
Females
Males
Metabolite name
Int. Sex P value *
HR
95% CI
P valuea
HR
95% CI
P valuea
0.102
Acetyl-lysine
0.97
0.75 - 1.25
0.795
0.79
0.68 - 0.93
0.003
0.070
Alanine
1.09
0.79 - 1.51
0.607
0.75
0.59 - 0.95
0.017
0.113
AMP
1.1
0.68 - 1.78
0.699
0.71
0.53 - 0.95
0.019
0.041
Argininosuccinic acid
1.02
0.77 - 1.34
0.906
0.71
0.54 - 0.93
0.012
0.009
Asparagine
1.45
0.91 - 2.32
0.119
0.74
0.56 - 0.98
0.039
0.115
Carnitine
3.23
0.23 - 44.44
0.382
0.38
0.23 - 0.65
<0.001
0.278
CMP
0.97
0.56 - 1.67
0.908
0.70
0.51 - 0.96
0.028
0.033
Creatinine
0.72
0.41 - 1.26
0.251
1.63
1.13 - 2.36
0.009
0.246
Cytidine
0.56
0.34 - 0.9
0.017
0.75
0.49 - 1.15
0.185
0.556
Fructose 6-phosphate
0.82
0.53 - 1.26
0.355
0.68
0.49 - 0.95
0.025
0.104
Glutathione
0.74
0.57 - 0.95
0.018
0.92
0.80 - 1.06
0.236
0.329
Glutathione disulfide
0.73
0.58 - 0.91
0.006
0.82
0.68 - 0.99
0.037
0.157
GMP
1.05
0.69 - 1.61
0.818
0.74
0.57 - 0.96
0.024
0.009
Hypoxanthine
1.87
0.57 - 6.19
0.304
0.32
0.21 - 0.51
<0.001
0.100
LysoPC(16:1)
1.05
0.75 - 1.47
0.765
0.77
0.61 - 0.96
0.023
0.294
LysoPE(18:1)
0.98
0.73 - 1.31
0.897
0.83
0.69 – 1.00
0.049
0.218
LysoPE(20:1)
0.97
0.77 - 1.23
0.812
0.84
0.71 - 0.98
0.028
0.070
LysoPE(22:5)
1.08
0.70 - 1.67
0.721
0.70
0.53 - 0.91
0.009
0.119
LysoPE(18:2)
1.07
0.70 - 1.63
0.767
0.73
0.55 - 0.95
0.021
0.013
Serine
1.39
0.72 - 2.69
0.329
0.59
0.41 - 0.85
0.005
0.206
Sphinganine-1-phosphate
0.92
0.59 - 1.44
0.715
0.67
0.48 - 0.94
0.022
0.206
Stearamide
0.91
0.62 - 1.33
0.629
0.70
0.53 - 0.92
0.011
0.086
Threonine
0.96
0.58 - 1.60
0.885
0.65
0.47 - 0.90
0.009
0.869
Xanthine
0.59
0.36 - 0.98
0.043
0.69
0.49 - 0.98
0.036
0.112
Xanthosine
1.01
0.73 - 1.38
0.972
0.72
0.52 - 0.99
0.044
a

Raw P value before FDR adjustment. *Each metabolite with sex-interaction P value. The abundance of each metabolite was treated as a continuous variable and
was log2 transformed.
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Principal Component Analysis results for females and males
Supplementary Figure 1. Results of
Principal Component Analysis (PCA) by
sex. Screen plot for females (A) and for
males (B) illustrated the explained
variance by top 10 components. PCA
biplot for females (C) and males (D)
indicated a poor overall survival (OS)
classification ability by considering the
first two components based on metabolite
abundance. Amino acids (e.g., threonine,
alanine, serine, and asparagine etc.) were
successfully distinguished and clustered
around at the positive direction of
dimension 2 for both females (C) and
males (D).
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Supplementary Table 5. Eigenvalue and variance of components retained for females and males. We only analyzed components with an eigenvalue greater than
1 based on the Kaiser rule1. For females, 19 dimensions were adopted in further analysis, which accounted for 83.23% of the total variance. For males, 20
dimensions were included with a cumulative variance of 83.70%.
Females
Males
Eigenvalue
Variance percent
Cumulative variance percent
Eigenvalue
Variance percent
Cumulative variance percent
Dim.1
18.93
20.81
20.81
17.45
19.18
19.18
Dim.2
15.59
17.13
37.94
14.37
15.79
34.96
Dim.3
9.39
10.32
48.26
9.44
10.38
45.34
Dim.4
4.23
4.65
52.91
4.08
4.49
49.83
Dim.5
3.39
3.73
56.64
3.87
4.25
54.08
Dim.6
3.10
3.41
60.05
3.07
3.38
57.46
Dim.7
2.70
2.96
63.01
2.90
3.19
60.65
Dim.8
2.25
2.47
65.48
2.57
2.82
63.47
Dim.9
1.93
2.12
67.60
2.25
2.48
65.95
Dim.10
1.89
2.08
69.67
2.12
2.33
68.28
Dim.11
1.73
1.90
71.58
1.77
1.95
70.23
Dim.12
1.68
1.85
73.43
1.69
1.86
72.08
Dim.13
1.49
1.64
75.06
1.63
1.79
73.87
Dim.14
1.41
1.55
76.62
1.52
1.67
75.54
Dim.15
1.39
1.53
78.15
1.47
1.61
77.15
Dim.16
1.29
1.41
79.56
1.42
1.56
78.72
Dim.17
1.22
1.34
80.90
1.28
1.41
80.13
Dim.18
1.11
1.22
82.12
1.16
1.27
81.40
Dim.19
1.01
1.11
83.23
1.08
1.19
82.58
Dim.20
1.01
1.11
83.70

1

KAISER, H. E (1960). The application of electronic computers to factor analysis. Education & Psychological Measurement, 20, 14I-151.
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Supplementary Table 6. Statistically significant results using CPH analysis for individual top 19 components for females and top 20 components (with
eigenvalues > 1) for males adjusted for clinical stage, tumor location, and age. No component was associated with OS for female patients. Component 5 and 19
were associated with RSF among females. Metabolites noted with (+) were positively associated with the corresponding component, and the higher the absolute
value of loading, the greater the relationship, vice versa. A component with HR > 1 was associated with an increased risk of poorer prognosis. E.g., component 5
was associated with both poor OS and RSF for males. Males with higher levels of succinate, creatinine, L-phenylalanine, and lower levels of carnitine and
cytidine have higher risks of all-cause mortality and CRC recurrence.

OS (Females)

Component
number
None

OS (Males)

5

Outcome

5
RSF (Females)
19
2
RSF (Males)
5

Influential metabolites:
(+): loading > 0.2; (-): loading <- 0.2
Succinate (+), Creatinine (+), L-Phenylalanine (-),
Carnitine (-), Cytidine (-)
Palmitic acid (+), Diacetylspermine (+), Stearic acid (+),
Oleic acid (+), Glutathione disulfide (-), Adenosine (-),
Xanthine (-)
Vitamin E (+), CMP, PC(36:2) (+), Lactate (+), DGlucuronate (+), Adenosine (+),
Ribulose 5-phosphate (+), AMP (+), ADP-ribose (+), LPhenylalanine (-), Carnitine (-), Cytidine (-)
Succinate (+), Creatinine (+), L-Phenylalanine (-),
Carnitine (-), Cytidine (-)

7

HR (95% CI)

P

-

-

1.20 (1.02-1.42)

0.026

1.72 (1.22-2.43)

0.002

1.91 (1.09-3.34)

0.023

0.87 (0.76-0.98)

0.027

1.34 (1.13-1.59)

0.001

C-index
(Se)
0.751
(0.052)
0.799
(0.048)
0.749
(0.063)
0.716
(0.06)
0.706
(0.07)

Any variable Violated
PH assumption
No
No
No
Yes
Yes

